Progesterone Receptor Negative Recruiting Phase 2 Trials for Paclitaxel (DB01229)

IndicationStatusPhase
DBCOND0038639 (Progesterone Receptor Negative)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02876107Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast CancerTreatment
NCT02957968Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast CaTreatment
NCT02883062Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast CancerTreatment
NCT02593175Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBCTreatment
NCT02689427Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast CancerTreatment
NCT02530489Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast CancerTreatment
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast CancerTreatment